Jaguar Health (JAGX) earnings
Jaguar Health earnings: last reported Wed, 19 Aug 2026, for the quarter ended Jun 2026.
Jaguar Health earnings callsJaguar Health earnings calls (JAGX)
Jaguar Health Q2 FY26 — Strategic Transformation to Rare Disease GI Focus
What went well
- Completed a transformative U.S. Commercial out-license agreement with Future Pak for Mytesi and Canalevia-CA1, bringing in $18 million upfront non-dilutive capital.
- Achieved stunning clinical results for crofelemer in MVID patients, with weekly parenteral support requirements reduced by up to 48% following over 12 months of therapy.
- Demonstrated significant reduction in parenteral support for SBS-IF patients, with requirements reduced by up to 40% over a year of treatment.
What to watch
- Prescription product net revenue decreased by 60% to $1.2 million in Q2 2026 compared to $2.9 million in Q2 2025, primarily due to the Future Pak licensing agreement.
- Net loss attributable to common shareholders increased by $2.3 million, from $10.4 million in Q2 2025 to $12.7 million in Q2 2026.
Performance −93.9% 1Y
1Y: $73.85 on 29 Sept 2025 → $4.5. High $81.55 (30 Sept 2025), low $0.32 (10 Sept 2026).
Quarterly results
Q2 FY26: revenue down 58.9% against the same quarter last year.
| Line item | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3 | 4 | 2 | 3 | 3 −1% | 3 −8% | 20 +816% | 1 −59% |
| EBITDA | -7 | -8 | -9 | -8 | -7 +0% | -21 −160% | 10 +208% | -8 +5% |
| Net profit | -10 | 29 | -10 | -10 | -10 +4% | -23 −181% | — | — |
How to read this
US$ million, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Balance sheet
| Year ending | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Reserves | -$166.90M | -$219.49M | -$266.95M | -$308.25M | -$346.48M | -$399.92M |
| Total liabilities | $25.64M | $41.41M | $48.81M | $45.87M | $44.45M | $57.01M |
| Fixed assets | $677.0K | $650.0K | $557.0K | $496.0K | $464.0K | $463.0K |
| Total assets | $42.84M | $53.27M | $47.45M | $50.76M | $53.42M | $38.32M |
How to read this
As filed on each reporting date, including interim balance sheets. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Insider filings
9 filings, all on Dec 11, 2025.
Open market
decisions to buy or sellNobody bought or sold JAGX on the open market in this window. The filings below are 9 awards.
Compensation
not trading decisions- 9
- Award — granted as compensation
Latest filings (16)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Dec 11, 2025 | MICEK JOHN Director | Award | 7,377 | $0 |
| Dec 11, 2025 | CONTE LISA A See Remarks | Award | 28,592 | $0 |
| Dec 11, 2025 | Wolin Jonathan S. See Remarks | Award | 11,740 | $0 |
| Dec 11, 2025 | King Steven R. See Remarks | Award | 11,740 | $0 |
| Dec 11, 2025 | Lizak Carol R. Chief Financial Officer | Award | 11,740 | $0 |
| Dec 11, 2025 | Jayasuriya Anula Director | Award | 5,870 | $0 |
| Dec 11, 2025 | Siegel Jonathan B. Director | Award | 7,377 | $0 |
| Dec 11, 2025 | BOCHNOWSKI JAMES J Director | Award | 6,363 | $0 |
| Dec 11, 2025 | Chaturvedi Pravin R Chief Scientific Officer | Award | 11,740 | $0 |
| May 17, 2025 | CONTE LISA A CEO and President | Option exercise | 2 | — |
| May 17, 2025 | King Steven R. See Remarks | Option exercise | 1 | — |
| Oct 8, 2024 | King Steven R. See Remarks | Award | 4,922 | $0 |
| Oct 8, 2024 | CONTE LISA A See Remarks | Award | 16,503 | $0 |
| Oct 8, 2024 | Wolin Jonathan S. See Remarks | Award | 4,922 | $0 |
| Oct 8, 2024 | Chaturvedi Pravin R Chief Scientific Officer | Award | 4,922 | $0 |
| Oct 8, 2024 | Lizak Carol R. Chief Financial Officer | Award | 4,280 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.